To include your compound in the COVID-19 Resource Center, submit it here.

Data Bytes: COVID-19 pipeline growth continues to flatten

BioCentury is providing this content for free given the urgent need for information about the coronavirus crisis. Further analysis can be found in our COVID-19 Resource Center. For more, sign up for our daily email.

This week, eight COVID-19 countermeasures entered the pipeline, down from 16 entrants last week. BioCentury’s COVID-19 Resource Center is now tracking 648 therapies and vaccines.

The newest preclinical vaccines in the pipeline include the protein-based T-VIVA-19 vaccine from Sorrento Therapeutics Inc. (NASDAQ:SRNE) and the engineered live-attenuated virus MV-014-210 from Meissa Vaccines Inc.

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers